Open an account

Verrica Pharmaceuticals

VRCA · NASDAQ

$3.47+$0.03 (+0.87%)TodayMarket closed ·
Prev close $3.44

About VRCA

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 76 full-time employees. The company went IPO on 2018-06-15. The firm's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. The company is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Employees
76
Headquarters
West Chester, Pennsylvania
Listed
Jun 15, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
verrica.com

VRCA key statistics

Market cap
61.76M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
52.82K
Volume
77.19K
Open price
$3.44
High today
$3.56
Low today
$3.30
52 Week high
$9.82
52 Week low
$3.28

Verrica Pharmaceuticals (VRCA) at a glance

As of Oct 20, 2026, Verrica Pharmaceuticals (VRCA) shares are priced at $3.47, giving the company a market cap of 61.76M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.30 and $3.56. The current price is 5.2% above the day's low and 2.5% below its high.

Volume so far is 77.19K shares, above the average of 52.82K shares a day.

Over the past year Verrica Pharmaceuticals has ranged from $3.28 to $9.82, and now sits 3% of the way up that range.

Verrica Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.54 per share against an estimate of -$0.4304.

The average analyst price target is $14.11, 306.6% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $14.11
Low
$9.09
Now
$3.47
High
$21.00

VRCA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 52.7% on average.

  1. Q3 FY24: reported -$4.90 per share against an estimate of -$3.74
  2. Q4 FY24: reported -$2.40 per share against an estimate of -$2.68
  3. Q1 FY25: reported -$1.00 per share against an estimate of -$0.9945
  4. Q2 FY25: reported $0.02 per share against an estimate of -$0.7191
  5. Q3 FY25: reported -$0.03 per share against an estimate of -$0.6885
  6. Q4 FY25: reported -$0.46 per share against an estimate of -$0.8102
  7. Q1 FY26: reported -$0.41 per share against an estimate of -$0.4629
  8. Q2 FY26: reported -$0.54 per share against an estimate of -$0.4304

VRCA news

  • Press releaseBusiness Wire

    VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm

  • Press releaseBusiness Wire

    VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA

  • Press releaseBusiness Wire

    Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseBusiness Wire

    Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

  • What to Expect from Verrica Pharmaceuticals's Earnings

  • Earnings Outlook For Verrica Pharmaceuticals

  • 12 Health Care Stocks Moving In Friday's After-Market Session

Similar companies

Companies in the same industry as Verrica Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.